Sotatercept (Winrevair): The Activin Trap That Made Pulmonary Arterial Hypertension a Treatable Disease, Not Just a Managed One (July 18, 2026)

Thirty years of dilating vessels that kept narrowing

Pulmonary arterial hypertension is a disease of the small arteries in the lungs. Their walls thicken, their cells proliferate, and the vessels progressively narrow until the right side of the heart cannot push blood through them. Until recently every approved PAH drug attacked the same half of the problem: tone. Endothelin receptor antagonists, PDE5 inhibitors and prostacyclin analogs all relax the pulmonary vasculature. They help - meaningfully - but they do not stop the cellular overgrowth that keeps closing the vessels down. Patients improved and then, over years, declined anyway. Sotatercept was the first approved therapy aimed at the other half: the remodeling itself.

What sotatercept actually is

Sotatercept (brand name Winrevair, nonproprietary sotatercept-csrk, formerly ACE-011 from Acceleron Pharma before Merck's acquisition) is not a small peptide. It is a recombinant fusion protein: the extracellular ligand-binding domain of human activin receptor type IIA, stitched to the Fc region of human IgG1. In practice it behaves as a decoy receptor - a ligand trap. Circulating activin A, activin B, GDF-8 (myostatin) and GDF-11 bind to it instead of to their real receptors on cells. That breadth is what distinguishes sotatercept from every other drug in the activin family: garetosmab neutralizes activin A alone, trevogrumab and apitegromab target myostatin, bimagrumab blocks the ActRII receptor itself, and taldefgrobep alfa is a myostatin-and-activin decoy. Sotatercept catches the widest net.

The signaling imbalance it corrects

PAH involves a tug-of-war between two arms of the TGF-beta superfamily. Activin and GDF ligands signal through SMAD2/3 and push pulmonary vascular cells toward proliferation and inflammation. BMPR-II signals through SMAD1/5/9 and holds that growth in check - and loss-of-function mutations in BMPR2 are the single most common genetic cause of heritable PAH. In PAH the balance tips toward the proliferative side. By sequestering the activin-class ligands, sotatercept tips it back. In animal models this does something vasodilators never do: it reverses established pulmonary vascular remodeling and suppresses the inflammation that accompanies it, which is why the compound is described as potentially disease-modifying rather than symptom-managing.

STELLAR: the trial that won approval

The pivotal Phase 3 STELLAR trial, published in the New England Journal of Medicine in 2023, enrolled adults with PAH already on stable background therapy and randomized them to sotatercept or placebo. It met its primary endpoint with a placebo-corrected improvement in 6-minute walk distance of 40.8 meters at week 24 (95% CI 27.5 to 54.1; p<0.001) - a large effect in a population where most incremental therapies move the needle by half that. Eight of nine secondary endpoints improved as well, including WHO functional class and pulmonary vascular resistance, and the risk of death or a clinical worsening event fell by 84% over a median 32.7 weeks. The FDA approved Winrevair in March 2024 on the strength of those data.

ZENITH: stopped early in the sickest patients

STELLAR studied patients in WHO functional class II and III. ZENITH went after the hardest cases: 172 adults in functional class III or IV at high risk of mortality, randomized one-to-one to sotatercept at a target dose of 0.7 mg/kg subcutaneously every three weeks or to placebo, both added to background PAH therapy. At a planned interim analysis the trial was stopped early for overwhelming efficacy. Sotatercept reduced the composite risk of all-cause death, lung transplantation and hospitalization for PAH by 76% versus placebo. Effects of that size on hard outcomes are uncommon in PAH, and they reframed the question from whether patients walk farther to whether they stay alive and out of the hospital. The Phase 3 HYPERION study, in patients diagnosed within the previous twelve months, met its own primary endpoint and was also halted early - continuing to give placebo to newly diagnosed patients was difficult to justify once ZENITH read out.

The expanded label

On October 27, 2025 the FDA approved an updated U.S. indication built on ZENITH. Winrevair is now indicated for adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. That last clause is the substantive change: the original label spoke to how far patients could walk, while the current one speaks to whether the disease progresses.

The safety trade: blood counts, not muscle

Trapping activins and GDF ligands has predictable hematologic consequences - sotatercept's ancestor was, after all, developed for anemia. The drug raises hemoglobin, and elevations of more than 2 g/dL above the upper limit of normal occurred in about 15% of treated patients; severe erythrocytosis can increase the risk of thromboembolic events or hyperviscosity. It also lowers platelets, with severe thrombocytopenia (below 50,000/mm3) in roughly 3 to 6% of patients, and serious bleeding has been reported. Consequently hemoglobin and platelet count must be checked before each of the first five doses and periodically thereafter, with dose adjustment or interruption as needed. The most common adverse reactions - infections, epistaxis, telangiectasia, diarrhea, headache, rash, increased hemoglobin, dizziness, erythema and gingival bleeding - trace the same vascular and hematologic biology. Sotatercept may also cause fetal harm and may impair female fertility.

Where it goes next - and what it means for the rest of the activin family

Merck is pushing beyond Group 1 disease. The Phase 2 CADENCE study reported positive topline results in November 2025 in adults with combined pre- and post-capillary pulmonary hypertension due to heart failure with preserved ejection fraction - WHO Group 2, a far larger population with no targeted therapy - showing meaningful reductions in pulmonary vascular resistance and prompting Phase 3 planning. The Phase 2 MOONBEAM study (NCT05587712) is the first dedicated trial in children aged 1 to 17. For the broader activin field, sotatercept matters as the benchmark: it is the only fully approved activin-axis drug, and it demonstrates both the therapeutic reach of blocking this pathway and the cost of blocking it broadly. The selective antibodies now in development - garetosmab for activin A, trevogrumab and apitegromab for myostatin, bimagrumab at the receptor - are all, in a sense, attempts to keep sotatercept's biology while narrowing its footprint.

Bottom line

Sotatercept is an FDA-approved prescription biologic for a serious, life-threatening disease, administered under specialist care with mandatory blood monitoring. It is not a wellness compound, a research chemical, or something to source outside the medical system. Its significance for anyone following peptide and protein therapeutics is conceptual: it showed that a ligand trap aimed at the activin axis can change the trajectory of a disease, not merely its symptoms - and it set the bar that every more selective activin-axis drug is now measured against.

Citations

1. [1] Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension (STELLAR) - New England Journal of Medicine (2023) Source
2. [2] U.S. FDA Approves Updated Indication for WINREVAIR Based on Phase 3 ZENITH Study - Merck (October 27, 2025) Source
3. [3] WINREVAIR Reduced Composite Risk of Death, Lung Transplantation and PAH Hospitalization by 76% in ZENITH - Merck Source
4. [4] Merck Announces Phase 3 HYPERION Study Met Primary Endpoint in Recently Diagnosed Adults with PAH - Merck Source
5. [5] WINREVAIR (sotatercept-csrk) for injection - U.S. Prescribing Information (Merck) Source

Related Articles

Research & Compounds

Apitegromab (SRK-015): The First Muscle-Targeted Myostatin Antibody to Win a Phase 3 - in SMA, and Now Obesity (July 14, 2026)

For two decades, drugging myostatin - the body's brake on muscle growth - was a graveyard of failed trials. Apitegromab changed that. Scholar Rock's antibody binds only the inactive precursor forms of myostatin, and in the Phase 3 SAPPHIRE trial it became the first muscle-targeted therapy to improve motor function in spinal muscular atrophy on top of SMN drugs. Now the same mechanism is showing up in obesity: in Phase 2 EMBRAZE, apitegromab preserved ~55% more lean mass during tirzepatide weight loss. Here is how it works, what the data show, and where its September 30, 2026 FDA decision stands.

PepTracker Pro Team

July 14, 2026 9 min read

apitegromabSRK-015Scholar Rock

Read

Research & Compounds

Garetosmab: Regeneron's Activin A Antibody Nearly Shuts Off Bone Growth in FOP - and Helps Save Muscle in Obesity (July 17, 2026)

Regeneron's anti-activin A antibody garetosmab (REGN2477) cut new bone lesions by ~90-94% and their volume by more than 99% in the Phase 3 OPTIMA trial for the ultra-rare disease FOP - and its BLA is now under FDA Priority Review with an August 2026 decision date. The same activin A blockade also makes it the muscle-sparing partner to trevogrumab in the COURAGE obesity program.

PepTracker Pro Team

July 17, 2026 8 min read

garetosmabREGN2477Regeneron

Read